Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Ibrahim Nakhoul"'
Autor:
Laurie E. McLouth, Yue Zheng, Stephanie Smith, F. Stephen Hodi, Uma N. Rao, Gary I. Cohen, Thomas T. Amatruda, Shaker R. Dakhil, Brendan D. Curti, Ibrahim Nakhoul, Sreenivasa R. Chandana, Charles L. Bane, David E. Marinier, Sandra J. Lee, Vernon K. Sondak, John M. Kirkwood, Ahmad A. Tarhini, Lynne I. Wagner
Publikováno v:
Quality of Life Research. 32:183-196
Autor:
Laurie E, McLouth, Yue, Zheng, Stephanie, Smith, F Stephen, Hodi, Uma N, Rao, Gary I, Cohen, Thomas T, Amatruda, Shaker R, Dakhil, Brendan D, Curti, Ibrahim, Nakhoul, Sreenivasa R, Chandana, Charles L, Bane, David E, Marinier, Sandra J, Lee, Vernon K, Sondak, John M, Kirkwood, Ahmad A, Tarhini, Lynne I, Wagner
Publikováno v:
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.
Trial E1609 demonstrated superior overall survival with ipilimumab 3 mg/kg (ipi3) compared to high-dose interferon (HDI) for patients with resected high-risk melanoma. To inform treatment tolerability, we compared health-related quality of life (HRQo
Autor:
Debu Tripathy, Joanne L. Blum, Bethany Sleckman, Kamal Patel, Ibrahim Nakhoul, Eric Gauthier, Monica Z. Montelongo, Zhe Zhang, Yao Wang, Gabrielle B. Rocque
Publikováno v:
Cancer Research. 83:P3-01
Background: The cyclin-dependent kinase 4/6 inhibitor palbociclib (PAL) is approved for the treatment of HR+/HER2– advanced breast cancer (ABC) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy or with fulvestrant (
Autor:
Joanne L. Blum, Debu Tripathy, Ibrahim Nakhoul, Sobha Kurian, Mayank Ajmera, Aldemar Montero, Yao Wang, Gabrielle B. Rocque, Bijoy Telivala, David Coblentz, Joseph C. Cappelleri, Richard C. Frank
Publikováno v:
Cancer Research. 80:PD10-03
Background: Palbociclib in combination with endocrine therapy (ie, an aromatase inhibitor [AI] or fulvestrant) is a current standard of care for patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−)
Autor:
MRIDULA TALARI, DAKOTA J ROBERTSON, MALLIKA VELICHETY, HAYTHAM ADADA, MAHMOUD K AMARNA, CAMELIA CHIRCULESCU, IBRAHIM NAKHOUL
Publikováno v:
Chest. 162:A1712
Autor:
Mohamad Adham Salkeni, Derrick W. Spell, Joanne L. Blum, Bethany G. Sleckman, Yao Wang, Gabrielle B. Rocque, John J. Migas, Aldemar Montero, Sami Diab, Sharon Wilks, Debu Tripathy, Ibrahim Nakhoul, Joseph C. Cappelleri, Daniel M. Anderson
Publikováno v:
Journal of Clinical Oncology. 37:200-200
200 Background: Real-world practice patterns often differ from treatment in clinical trials. We assessed real-world standard-of-care treatment with palbociclib (PAL) in the context of previously reported PALOMA trial results. Methods: POLARIS is a pr
Autor:
Marian M Varda, Bhavesh Balar, Stuart L. Goldberg, Ibrahim Nakhoul, Philip A. Philip, Tracy Proverbs-Singh, Andrew D. Norden, John Marshall, Jin S. Lee
Publikováno v:
Journal of Clinical Oncology. 36:e15622-e15622
e15622Background: National guidelines (NCCN 2016) recommend profiling for microsatellite instability (MSI) and mismatch repair (MMR) for all patients (pts) with colon cancer. Evaluations may identi...
Autor:
Roy Mackintosh, Nashat Y. Gabrail, Haresh S. Jhangiani, Robert Vescio, Alberto Bessudo, Ashkan Lashkari, James R. Berenson, Tanya M. Spektor, Michael Oren Robinson, Tina Maluso, Regina A. Swift, Samir V. Kubba, Jeffrey D. Neidhart, Alexa Cohen, Ibrahim Nakhoul
Publikováno v:
Journal of Clinical Oncology. 36:e20012-e20012
e20012Background: Pomalidomide (POM) is a third–generation immunomodulatory drug shown to be safe and effective for the treatment of relapsed/refractory multiple myeloma (RRMM) patients (pts) previ...
Autor:
Michael Oren Robinson, Tina Maluso, Nashat Y. Gabrail, Ashkan Lashkari, Alexa Cohen, Roy Mackintosh, Ibrahim Nakhoul, Samir V. Kubba, Jeffrey D. Neidhart, James R. Berenson, Shahrooz Eshaghian, Alberto Bessudo, Robert Vescio, Tanya M. Spektor, Regina A. Swift, Haresh S. Jhangiani
Publikováno v:
Journal of Clinical Oncology. 35:e19528-e19528
e19528 Background: Pomalidomide (POM) is a third –generation immunomodulatory drug shown to be safe and effective for the treatment of relapsed/refractory multiple myeloma (RRMM) for patients (pts) previously treated with bortezomib and lenalidomid
Autor:
Michael L. Grossbard, Jonah Shulman, Mala Varma, Tahir Mirzoyev, Maria Machuca, Ibrahim Nakhoul, Peter Kozuch, Ilan Shapira, Bruce Culliney, David Lucido
Publikováno v:
Blood. 120:3343-3343
Abstract 3343 Background Anti-Rh(D) is an immune globulin against the Rh group and is used for the treatment of immune thrombocytopenia (ITP). A 75 μcg/kg dose induces an overnight response in 92% of patients and a median response duration of 46 day